| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2412dd2043f5bb835a2d9c3b47a47708
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0822fdf79e805dbc3a4aa3033a9f7305
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ea7da26cb077e35d67c7703ba5e49d7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_596f8ff15efe306bf1841c5db819a8fa |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H04L41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-30 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/H04L12-24 |
| filingDate |
1995-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1c9282f113eac4de3b40cad496a96f2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21202232ab4507abcbfc149a99d74760
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d8ec123a3e76d9213dd7e0a64a2fb09 |
| publicationDate |
1996-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9601125-A1 |
| titleOfInvention |
Use of insulin and igf-i |
| abstract |
The invention relates to the use of a combination of insulin and an Insulin-like growth factor I (IGF-I) in the manufacture of a medicament for counteracting a decrease in nitrogen balance and for counteracting a decrease in protein synthesis and which can be used for treatment of catabolism which is a protein catabolism due to glucocorticoid excess. The ratio of IGF-I to insulin in the medicament preferably ranges from 30:1 to 2:1, based on molecular weight. The medicament may be suitable for the treatment of patients with high serum level of IGFBP1 or other low molecular weight BPs. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6559122-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9806423-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5994303-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-102012020496-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5783556-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7186686-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1114644-A1 |
| priorityDate |
1994-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |